Feb 25, 2021
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 22, 2021
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
Feb 17, 2021
ESSA Pharma Announces Pricing of Public Offering of Common Shares
Feb 16, 2021
ESSA Pharma Announces Proposed Public Offering of Common Shares
Feb 11, 2021
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
Feb 11, 2021
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
Jan 13, 2021
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
Dec 15, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
Nov 25, 2020
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
Nov 10, 2020
ESSA Pharma to Participate in Upcoming Investor Conferences
Oct 26, 2020
ESSA Pharma Inc. Announces Delisting from the TSX-V
Oct 24, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
Oct 19, 2020
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
Sep 21, 2020
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
Sep 17, 2020
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
Sep 14, 2020
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Sep 10, 2020
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
Aug 06, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
Jul 31, 2020
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
Jul 28, 2020
ESSA Pharma Announces Pricing of Public Offering of Common Shares